Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

Healthcare Diagnostics & Research
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma... see more

Recent & Breaking News (CSE:BUX)

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Newsfile January 15, 2026

BioMark: 2025 Achievements & 2026 Vision

Newsfile December 31, 2025

BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors

Newsfile December 30, 2025

BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program

Newsfile December 23, 2025

BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala

Newsfile December 1, 2025

CSE Bulletin: MOC Eligibility Update

Newsfile November 27, 2025

BioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy

Newsfile November 12, 2025

BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

Newsfile October 7, 2025

BioMark Secures Key Patents in Asia's Largest Markets for Early Lung Cancer Liquid Biopsy

Newsfile September 29, 2025

BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

Newsfile August 12, 2025

BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships

Newsfile August 5, 2025

BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026

Newsfile July 30, 2025

BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology

Newsfile May 20, 2025

BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of Its Early-Stage Lung Cancer Test

Newsfile May 12, 2025

BioMark Diagnostics Announces Uplisting to OTCQB Venture Market

Newsfile May 8, 2025

BioMark Announces the Final Closing of Oversubscribed Private Placement

Newsfile March 31, 2025

BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform

Newsfile March 26, 2025

BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025

Newsfile February 28, 2025

BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction

Newsfile December 10, 2024

BioMark Expands Its Liquid Biopsy Platform with Two Groundbreaking Publications in Breast Cancer Detection

Newsfile November 5, 2024

Podcasts